Replies to post #225428 on Biotech Values

[DewDiligence]

Scary: MORF +135% on_phase-1_SAD_data_in_healthy_volunteers!

https://finance.yahoo.com/news/morphic-reports-positive-interim-results-120000944.html

The drug in question, MORF-057, is intended to treat IBD.

p.s. Stock -9%/AH on public offering (https://finance.yahoo.com/news/morphic-therapeutic-announces-proposed-public-210100136.html ).